Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MRTX > SEC Filings for MRTX > Form 8-K on 29-Sep-2016All Recent SEC Filings

Show all filings for MIRATI THERAPEUTICS, INC.

Form 8-K for MIRATI THERAPEUTICS, INC.


29-Sep-2016

Change in Directors or Principal Officers, Financial Statements and Exh


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On September 27, 2016, the Board of Directors (the "Board") of Mirati Therapeutics, Inc. (the "Company"), upon recommendation of the Nominating and Corporate Governance Committee of the Board, elected Bruce L.A. Carter, Ph.D. to the Board, effective immediately. Dr. Carter's term of office expires at the Company's 2017 annual meeting of stockholders or when his successor is duly elected and qualified, or his earlier death, resignation or removal. The Board also appointed Dr. Carter to serve as a member of the Audit Committee of the Board (the "Audit Committee") and Compensation Committee of the Board (the "Compensation Committee").

In accordance with the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Policy"), upon his appointment to the Board, Dr. Carter received an initial grant consisting of a nonstatutory stock option to purchase 25,000 shares of the Company's common stock (the "Common Stock"), which shares will vest in a series of 36 equal monthly installments. In accordance with the Policy, Dr. Carter will be entitled to receive a $40,000 annual cash retainer for service as director, a $7,500 annual cash retainer for service as a member of the Audit Committee, a $5,000 annual cash retainer for service as a member of the Compensation Committee, and will be eligible to receive additional equity compensation in the future. Dr. Carter has entered into the Company's standard form of indemnification agreement. The Company is not aware of any transaction involving Dr. Carter requiring disclosure under Item 404(a) of Regulation S-K.

On September 29, 2016, the Company issued a press release announcing Dr. Carter's appointment to the Board, a copy of which is attached hereto as Exhibit 99.1.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No. Description
99.1 Press Release dated September 29, 2016


  Add MRTX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MRTX - All Recent SEC Filings
Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.